VivoSeq
Oncology

Bone Metastasis

23

Pipeline Programs↗

2

Active Trials↗

12

Companies Involved↗

Bone Metastasis is an emerging landscape with 23 programs across 12 companies. The most active players are Bayer, Fresenius Kabi Oncology Ltd., Takeda. 2 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

0/100

Mech. Concentration

19/100

Completion Rate

79/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 2F

Fresenius Kabi Oncology Ltd.

1 program

Phase 2Takeda logo

Takeda

1 program

Phase 2Astellas logo

Astellas

1 program

Phase 2A

Avyxa

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

21 of 24 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody28%Protein / enzyme14%

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 100% of 25 pipeline programs.

Analysis

Trial Status

32

clinical trials

Completed22 · 69%
Terminated4 · 13%
Withdrawn2 · 6%
Unknown status2 · 6%
Active, not recruiting1 · 3%
Recruiting1 · 3%

Clinical Trials

Trial Activity

32 trials

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Recruiting·WWashington University School of Medicine·Phase 1/2·NCT06374459·152 enrolled
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
Active, not recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT03317392·145 enrolled
Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer
Completed·Amgen logoAmgen·Phase 3·NCT00286091·1,435 enrolled
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
Completed·Novartis logoNovartis·Phase 4·NCT00334139·411 enrolled
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
Completed·Pfizer logoPfizer·Phase 3·NCT02609828·156 enrolled
Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
Completed·Novartis logoNovartis·Phase 4·NCT00237159·284 enrolled
Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis
Completed·CCarolina Research Professionals, LLC·Phase 2·NCT02507570·40 enrolled
Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer
Completed·Amgen logoAmgen·Phase 3·NCT01824342·18 enrolled
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
Completed·Novartis logoNovartis·Phase 4·NCT00035997·261 enrolled
Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
Completed·IInstitut Bergonié·Phase 1·NCT02517918·23 enrolled
Bone Metastasis and Surgery in Breast Cancer
Completed·FFederation of Breast Diseases Societies·N/A·NCT02125630·460 enrolled
Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors
Completed·SSeverance Hospital·Phase 2·NCT02784652·60 enrolled
Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
Completed·Novartis logoNovartis·Phase 4·NCT00237146·38 enrolled
Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis
Completed·UUniversity of Louisville·N/A·NCT00264082·30 enrolled
Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid
Completed·Novartis logoNovartis·Phase 4·NCT00172029·116 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)